GLP-3 RT
Triple-Receptor GLP Research Compound - Triple-receptor GLP research compound (GLP-1/GIP/glucagon class).
GLP-3 RT is a triple-receptor research compound characterized in vitro across the GLP-1, GIP and glucagon receptor families. Supplied as a reference standard for receptor-pharmacology and analytical work.
The glucagon arm is what separates this class from the dual-incretin tools: adding a third receptor to the same molecule brings hepatic and energy-expenditure signaling into one construct, so a selectivity panel can be run against a single reference instead of three separate ones. Published in-vitro work reports potency at each receptor independently, which is why lot identity and purity carry more weight here than for a single-target control.
GLP-3 RT specifications
- CAS number
- 2381089-83-2
- Molecular formula
- C221H342N50O68
- Molecular weight
- 4731.32 g/mol
- Sequence
- Triple-agonist research peptide
- Residues
- 39 residues
- Presentation
- Lyophilized powder
- Documented purity
- 99.44% by HPLC
- Available sizes
- 10mg ($65), 30mg ($130), 60mg ($205)
- Archived COA lots
- 21
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- Incretin-receptor engagement - Studied for combined GLP-1 and GIP receptor engagement in in-vitro cAMP assay systems.
- Glucagon-receptor engagement - The glucagon-receptor arm is characterized separately in receptor-binding and cAMP assays.
Reported mechanisms in the literature
- Incretin-receptor engagement - Studied for combined GLP-1 and GIP receptor engagement in in-vitro cAMP assay systems. (Drucker et al.)
- Glucagon-receptor engagement - The glucagon-receptor arm is characterized separately in receptor-binding and cAMP assays. (Preclinical literature)
What GLP-3 RT is researched for
- Triple-receptor engagement - Studied as a triple GLP-1/GIP/glucagon agonist for simultaneous receptor engagement in in-vitro cAMP assays. (Coskun et al.)
- Receptor selectivity - Investigated for combined incretin-receptor binding selectivity against single- and dual-agonist comparators. (Drucker et al.)
GLP-3 RT certificates of analysis on file
Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.
| Lot | Tested | Size | Laboratory | HPLC purity | Identity | Certificate |
|---|---|---|---|---|---|---|
| GLP3-101926-10 | 22 Oct 2026 | 10mg | ILS Laboratories | 99.90% | Confirmed (HPLC retention time) | COA PDF |
| 5MF77J | 14 Oct 2026 | 50mg | Freedom Diagnostics | 99.90% | Confirmed (LC-MS/MS) | COA PDF |
| NMWDQ5 | 9 Oct 2026 | 60mg | Freedom Diagnostics | 99.99% | Confirmed (LC-MS/MS) | COA PDF |
| 9CPRT5 | 3 Oct 2026 | 10mg | Freedom Diagnostics | 99.97% | Confirmed (LC-MS/MS) | COA PDF |
| GC1XH9 | 3 Oct 2026 | 30mg | Freedom Diagnostics | 99.97% | Confirmed (LC-MS/MS) | COA PDF |
| 5EPZBW | 29 Sep 2026 | 10mg | Freedom Diagnostics | 99.44% | Confirmed (LC-MS/MS) | COA PDF |
| ZK58U8 | 15 Sep 2026 | 60mg | Freedom Diagnostics | 99.31% | Confirmed (LC-MS/MS) | COA PDF |
| Z1PT2K | 12 Sep 2026 | 30mg | Freedom Diagnostics | 99.92% | Confirmed (LC-MS/MS) | COA PDF |
| 4ZF4G7 | 12 Sep 2026 | 60mg | Freedom Diagnostics | 99.74% | Confirmed (LC-MS/MS) | COA PDF |
| 3KT3H0 | 25 Jul 2026 | 10mg | Freedom Diagnostics | 99.91% | Confirmed (LC-MS/MS) | COA PDF |
| Y4AWYQ | 13 Jul 2026 | 30mg | pH Solutions | 99%+ | Confirmed (LC-MS/MS) | COA PDF |
| 2NPVBM | 9 Jul 2026 | 60mg | pH Solutions | 99%+ | Confirmed (LC-MS/MS) | COA PDF |
| Auth2607030208 | 7 Jul 2026 | 10mg | Freedom Diagnostics | 99.90% | Confirmed (LC-MS/MS) | COA PDF |
| Auth2607030209 | 7 Jul 2026 | 30mg | Freedom Diagnostics | 99.59% | Confirmed (LC-MS/MS) | COA PDF |
| Auth2606090074 | 12 Jun 2026 | 30mg | Freedom Diagnostics | 99.90% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2606090073 | 11 Jun 2026 | 10mg | Freedom Diagnostics | 99.91% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2606090074 | 9 Jun 2026 | 20mg | Freedom Diagnostics | 99.90% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2605270307 | 27 May 2026 | 10mg | Freedom Diagnostics | 99.81% | Confirmed (LC-MS/MS) | COA PDF |
| Auth2605110187 | 14 May 2026 | 60mg | Freedom Diagnostics | 99.66% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2605110186 | 11 May 2026 | 30mg | Freedom Diagnostics | 99.62% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2604140196 | 14 Apr 2026 | 10mg | Freedom Diagnostics | 99.79% | Confirmed (LC-MS/MS) | COA PDF |
GLP-3 RT sizes and pricing
| Size | Price | Per mg |
|---|---|---|
| 10mg | $65 | $6.50 per mg |
| 30mg | $130 | $4.33 per mg |
| 60mg | $205 | $3.42 per mg |
Published literature on GLP-3 RT
The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.
GLP-3 RT frequently asked questions
What class of compound is GLP-3 RT?
A triple-receptor research compound characterized across the GLP-1, GIP and glucagon receptor families in in-vitro receptor pharmacology.
Is it approved for human use?
No. It is a research material only, supplied for in-vitro laboratory study. It is not a medicine and is not for human or animal consumption.
What molecular data is available?
As a proprietary research formulation, structural identifiers are documented on the lot Certificate of Analysis rather than a public monograph.
Documented to 99.44% purity by HPLC · third-party COA every lot · from $65 · For laboratory research use only.
Related Metabolic compounds
- GLP-1 S - Single-agonist GLP-1 research compound.
- GLP-2 TZ - Dual GIP/GLP-1 receptor co-agonist studied in glucose-handling and energy-balance research.
- Cagrilintide - Acylated amylin analogue studied for amylin and calcitonin receptor signaling.
- GLP-3 RT + Cagri - GLP-3 RT (10mg) co-formulated with Cagrilintide (2mg) in one vial.
- 5-Amino-1MQ - Small-molecule NNMT inhibitor studied in metabolism research.
- MOTS-c - Mitochondrial-derived peptide studied for metabolic regulation.